



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

#48

AUG 19 1994

Steven J. Lee
Kenyon & Kenyon
One Broadway
New York, New York 10004

Re: Patent Term Extension
Application for
U.S. Patent No. 4,692,435

NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,692,435 issued September 8, 1987, which claims the human drug product Lovenox, is eligible for patent term extension under 35 USC § 156. The period of extension has been determined to be 1,116 days.

The period of extension has been calculated using the FDA determination of the length of the regulatory review period published in the Federal Register of November 26, 1993. Under 35 USC § 156(c):

$$\begin{aligned}\text{Period of Extension} &= 1/2 (\text{Testing Phase}) + \text{Approval Phase} \\ &= 1/2 (1,322) + 455 \\ &= 1,116 \text{ days}\end{aligned}$$

Since the regulatory review period began after the patent issue date, the entire period has been considered in the above calculation. No determination of a lack of due diligence was made.

The limitation of 35 USC § 156(g)(6) and the 14 year exception of 35 USC § 156(c)(3) do not operate to reduce the period determined above.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue to the applicant for extension of the term of Patent No. 4,692,435 a certificate of extension, under seal, for a period of 1,116 days.

U.S. Patent No. 4,692,435

Upon issuance of the certificate of extension the following information will be published in the Official Gazette:

U.S. Patent No.:	4,692,435
Granted:	September 8, 1987
Applicant:	Jean-Claude Lormeau et al.
Owner of Record:	Choay, S.A.
Title:	MUCOPOLYSACCHARIDE COMPOSITION HAVING A REGULATORY ACTION ON COAGULATION, MEDICAMENT CONTAINING SAME AND PROCESS OF PREPARATION
Classification:	514/56
Product Trade Name:	Lovenox
Term Extended:	1,116 days

C. E. Van Horn

Charles E. Van Horn
Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 11-44
Rockville, MD 20857

RE: Lovenox

FDA Docket No.: 93E - 0214